Purple Biotech Ltd. (PPBT) is an Israeli clinical-stage immuno-oncology company whose American Depositary Receipts (ADRs) trade on the Nasdaq. The $17 figure now dominating the stock's discussion is not arbitrary — it is the published 12-month price target of H.C. Wainwright analyst Emily Bodnar, the only brokerage currently maintaining an active target on the name. The firm lowered its objective from $30 to $17 in August 2026 while keeping a Buy rating, citing the company's "low" cash position and a sharp increase in operating expenses. For a stock trading near $2, a $17 target represents a dramatic re-rating, which is why the question "can Purple Biotech reach $17?" has become a focal point for speculative traders and investors.
Purple Biotech develops next-generation multi-specific T cell engagers designed to activate both T cells and natural killer (NK) cells against solid tumors. Its CAPTN-3 platform is built around masked, tri-specific antibody candidates, led by IM1240. The company is pre-revenue, meaning it generates no product sales, and operates with a market capitalization measured in only a few million dollars — placing it firmly in micro-cap, high-risk territory.
The balance sheet is the defining constraint. As of the second quarter of 2026, Purple Biotech disclosed a cash balance of roughly $6.1 million, which management expects to fund operations only into mid-2027. Advancing IM1240 into a Phase 1 trial — now targeted for 2027, with initial results potentially in 2028 — will almost certainly require either a strategic partnership or additional dilutive capital raises. That funding overhang hangs over every rally in the shares.
Several catalysts support the possibility of a sustained move upward, even if $17 remains a distant objective. The company reported encouraging preclinical data for IM1240 in its Q2 2026 update, including tolerability in toxicology studies at doses substantially higher than non-masked comparators and strong responses in anti-PD-1 resistant lung cancer biopsy models. Separately, the U.S. Patent and Trademark Office issued a Notice of Allowance covering tri-specific antibody designs tied to the CAPTN-3 platform, a step that strengthens the company's intellectual property position and could enhance the value of any future licensing or partnership deal.
From a technical standpoint, the stock has been carving out a short-term uptrend, with higher lows forming from mid-August into early September 2026. The 52-week range still reflects a high near $24, meaning $17 sits below the stock's recent historical peak rather than above it — an important distinction for traders assessing whether the level is recoverable. Positive preclinical readouts, a partnership announcement, or an unexpected financing on favorable terms could each serve as the catalyst for the next leg higher.
The obstacles are substantial. Purple Biotech has no approved products and no human clinical data for its lead assets, so the entire investment thesis rests on preclinical science that has not yet been validated in patients. Cash burn continues, and the runway extends only into mid-2027. Each capital raise dilutes existing shareholders, and the 1-for-10 reverse split in March 2026 underscores the company's history of share-price erosion.
The analyst community is thin and divided. H.C. Wainwright carries a Buy with a $17 target, but other rating systems have issued Sell or Hold-equivalent signals in 2026, reflecting skepticism about the company's ability to fund development without significant dilution. With only a handful of analysts covering the name and extremely thin average trading volume, price moves can be abrupt in both directions.
The gap between the $17 analyst target and the current stock price is unusually wide — roughly a tenfold difference. Such a spread is common in preclinical biotech, where a single successful clinical milestone can re-rate a stock many times over, but it also signals that the target embeds a high degree of optimism about future data and financing outcomes. Investors should treat the $17 figure less as a near-term forecast and more as a scenario that assumes successful Phase 1 initiation, continued positive data, and resolution of the funding question.
For traders monitoring volatile, catalyst-driven names such as Purple Biotech, AI Daily Buy/Sell Signals offers a way to track changing conditions in real time. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual screening allows. Explore the AI Daily Buy/Sell Signals to see how automated analysis can support your own decision-making process.
Reaching $17 is not impossible for PPBT, but it should be viewed as a low-probability, high-upside scenario rather than a near-term expectation. The strongest supporting factors are the CAPTN-3 platform's preclinical promise, the recent patent allowance, and a published analyst target that validates the bull case. The primary risks are equally clear: a shrinking cash runway, no revenue, a dependence on dilutive financing, and the absence of human clinical data. Going forward, investors should monitor IM1240's progression toward the clinic, any partnership or licensing announcements, quarterly cash disclosures, and how management addresses the funding gap. The gap between roughly $2 and $17 will narrow only if the science and the balance sheet improve together.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PPBT has been loosely correlated with SNTI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PPBT jumps, then SNTI could also see price increases.
| Ticker / NAME | Correlation To PPBT | 1D Price Change % | ||
|---|---|---|---|---|
| PPBT | 100% | -1.15% | ||
| SNTI - PPBT | 57% Loosely correlated | +1.93% | ||
| BCYC - PPBT | 32% Poorly correlated | +0.78% | ||
| ATOS - PPBT | 32% Poorly correlated | +7.26% | ||
| APLM - PPBT | 31% Poorly correlated | -5.62% | ||
| CCCC - PPBT | 27% Poorly correlated | +3.24% | ||
More | ||||